Aimmune Therapeutics, Inc. 4
4 · Aimmune Therapeutics, Inc. · Filed Feb 26, 2016
Insider Transaction Report
Form 4
Knapp Jeffrey H
Chief Operating Officer
Transactions
- Award
Common Stock, $0.0001 par value
2016-02-26+5,000→ 5,000 total - Award
Stock Option (right to buy)
2016-02-26+250,000→ 250,000 totalExercise: $16.93Exp: 2026-02-26→ Common Stock (250,000 underlying)
Footnotes (2)
- [F1]These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in full on February 1, 2017.
- [F2]The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 1, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.